VetMedFeline idiopathic cystitis: does a synthetic facial pheromone diffuser vs placebo reduce recurrence of lower urinary signs? — MAYBE (weak evidence) (the treatment made no difference)
In cats with idiopathic cystitis, does a synthetic facial pheromone diffuser vs placebo reduce recurrence of lower urinary signs?
Shelf #711 · gate-verified and displayed under the developer's blinded-trial rule
MAYBE (weak evidence) (the treatment made no difference): The only primary trial is a pilot. In Gunn-Moore & Cameron 2004, a randomised, double-blinded, placebo-controlled crossover pilot study, 12 cats with recurrent feline idiopathic cystitis were enrolled and 9 completed; there were no statistical differences between synthetic feline facial pheromone and placebo on any measure. The numbers leaned toward pheromone without reaching significance — total days with clinical signs of cystitis 30 on pheromone versus 69 on placebo (mean per cat 4.3 ± 6.7 vs 9.9 ± 19.1), episodes of cystitis 9 versus 10 (1.3 ± 2.0 vs 1.4 ± 2.1 per cat), overall clinical score totals 1667 versus 2009 — in a sample far too small, with standard deviations larger than the means, for those trends to establish an effect. The 2025 systematic review of recurrent feline idiopathic cystitis management (22 studies included) reaches the same position from the whole literature: little evidence to support the use of feline facial pheromone. Design class (a): randomisation and blinding are both established by the carded primary record (Gunn-Moore & Cameron 2004, 'randomised, double-blinded, placebo-controlled, crossover pilot study'). The honest limits: 9 completing cats, owner visual-analogue outcomes, a crossover with 2-month periods, and the record describes the environment being treated daily with pheromone or placebo — it does not establish that a continuously running diffuser (the form in this shelf's question) was the delivery method tested, so the result should not be silently transported to diffuser use. Drafted Nov 10, 2026 (VetMed build, topic #711); all figures from abstracts fetched and verified at drafting.
Gunn-Moore 2004: no statistical difference between synthetic feline facial pheromone and placebo in 9 completing cats with recurrent idiopathic cystitis (the treatment made no difference), with non-significant trends toward fewer sign days on pheromone
Randomised, double-blinded, placebo-controlled, crossover pilot study (record's own wording; publication types include Randomized Controlled Trial)
Who: Cats: 12 cats with recurrent feline idiopathic cystitis enrolled, of whom 9 completed the randomised, double-blinded, placebo-controlled crossover pilot study. The cats' environment was treated daily with either synthetic feline facial pheromone (FFP) (the record names the product as Feliway; Ceva Animal Health) or placebo for 2 months, after which the treatment groups were reversed. Owners used visual analogue scales to define the severity of their cat's clinical signs and behavioural changes. The record describes daily environmental treatment; it does not state that a plug-in diffuser was used.
Result: Five (56%) owners stated their cat's overall health was better when using FFP; four (44%) noticed no difference between FFP and placebo. There were no statistical differences between the two treatment groups. There was a trend for cats exposed to FFP to show fewer days with clinical signs of cystitis (FFP total 30, mean per cat 4.3 ± 6.7; placebo total 69, mean 9.9 ± 19.1), a lower overall clinical score (1667 total, 238 ± 476 per cat; placebo 2009 total, 287 ± 425), a reduced number of episodes of cystitis (9 total, 1.3 ± 2.0 per cat; placebo 10 total, 1.4 ± 2.1), and reduced negative behavioural traits (-128 total, -18.3 ± 65.8 per cat; placebo -73 total, -10.4 ± 35.1).
Watch out: A pilot in every sense: 9 completing cats, standard deviations larger than the means on the headline trend (9.9 ± 19.1 placebo days), and owner-reported visual analogue outcomes. The trend numbers are carded exactly as the record gives them and are not an effect — with this sample size the study could neither confirm nor exclude a modest benefit, and a crossover design in a waxing-and-waning condition is vulnerable to period effects the record does not address.
Gunn-Moore DA, Cameron ME. A pilot study using synthetic feline facial pheromone for the management of feline idiopathic cystitis. J Feline Med Surg. 2004;6(3):133-8. PMID: 15135349. Registry ID: none in the record. MeSH: Animal Husbandry · Animals · Cat Diseases/prevention & control* · Cats · Cross-Over Studies · Cystitis/prevention & control, veterinary* · Double-Blind Method · Eliminative Behavior, Animal/drug effects* · Female · Male · Pain Measurement/veterinary · Pheromones/administration & dosage* · Pilot Projects · Recurrence · Treatment Outcome
Macleod 2025: across the recurrent-FIC literature there is little evidence to support the use of feline facial pheromone, while multimodal environmental modification and therapeutic urinary diets have the strongest support
Systematic review of management strategies for recurrent feline idiopathic cystitis (record's own wording: 'a systematic review'; 22 studies included)
Who: Cats (literature base): peer-reviewed primary literature on therapeutic strategies for recurrent feline idiopathic cystitis, identified by searching three electronic databases (Discover, Scopus and PubMed) with two-stage screening; 22 studies were included in the final review, categorised by seven management strategies — environmental modification, dietary manipulation, anti-inflammatory drugs, amitriptyline, glycosaminoglycans, prazosin, and intravesical lidocaine.
Result: Two studies assessed environmental manipulation, with results showing encouraging evidence for multimodal environmental modification but little evidence to support the use of feline facial pheromone. Five papers examined dietary manipulation, with good evidence for therapeutic urinary diets and for increasing the moisture content of a cat's diet. No evidence supported anti-inflammatory drugs or glycosaminoglycans; prazosin showed no evidence of benefit in three placebo comparisons; and of three amitriptyline studies, two indicated short-term use is not supported and one long-term study suggested it may be useful in some refractory cases. The authors conclude multimodal environmental modification and therapeutic urinary foods currently have the strongest evidence and that the overall lack of high-quality studies emphasises the need for critical evaluation of this literature.
Watch out: A systematic review without a pooled pheromone effect estimate in its abstract — its pheromone conclusion ('little evidence to support') summarises the same small primary base carded above rather than adding a new trial, so it should not be counted as independent confirmation of a null; its value here is showing no later, larger pheromone trial has changed the picture in the literature it screened.
Macleod B, Laven LJ, Laven RA, Hill KE. Understanding the current evidence base for the commonly recommended management strategies for recurrent feline idiopathic cystitis: a systematic review. N Z Vet J. 2025;73(4):233-245. PMID: 40147044. Registry ID: none in the record. MeSH: Animals · Cats · Cystitis*/veterinary, therapy · Cat Diseases*/therapy · Anti-Inflammatory Agents/therapeutic use · Prazosin/therapeutic use
Synthesis: one 9-cat randomised double-blinded placebo-controlled crossover pilot found no statistical difference between synthetic facial pheromone and placebo for recurrent idiopathic cystitis, and a 2025 systematic review found little evidence to support pheromone use — MAYBE (weak evidence)
Synthesis
Who: Synthesis of the cards above: Gunn-Moore & Cameron 2004 (12 cats enrolled, 9 completed, randomised double-blinded placebo-controlled crossover, 2-month periods, owner visual analogue scales) and Macleod 2025 (systematic review, 22 studies of recurrent feline idiopathic cystitis management strategies).
Result: (1) Sign days: totals 30 on pheromone versus 69 on placebo (means 4.3 ± 6.7 vs 9.9 ± 19.1 per cat), not statistically different. (2) Episodes: 9 on pheromone versus 10 on placebo (1.3 ± 2.0 vs 1.4 ± 2.1 per cat), not statistically different. (3) Owner impression: 5 of 9 owners (56%) rated overall health better on pheromone, 4 (44%) noticed no difference. (4) Whole literature: little evidence to support feline facial pheromone for recurrent FIC (Macleod 2025), with stronger support for multimodal environmental modification and therapeutic urinary diets — different interventions from the pheromone question on this shelf.
Watch out: The evidence base is one pilot trial: absence of a shown difference in 9 cats is not proof that pheromone can never help any cat, and the shelf does not address pheromone for other indications (travel, hospitalisation, inter-cat tension), other pheromone products such as appeasing or intercat pheromones, or use combined with environmental modification and diet — the strategies the review found best supported. The tested delivery was daily environmental treatment as described in the record, not an established plug-in diffuser protocol.
Synthesis of Gunn-Moore DA, Cameron ME. PMID: 15135349; Macleod B et al. PMID: 40147044. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.